Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamibarotene in ADPKD
NCT06289998Phase 2Active, not recruiting
- Sponsor
- Rege Nephro Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tamibarotene in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Rege Nephro Co., Ltd.. Started Dec 2023; status: active, not recruiting.
02
Drugs
tamibarotene
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT06289998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06289998.